ProQR Therapeutics N.V. (PRQR)
- Previous Close
2.0000 - Open
2.0100 - Bid 1.9700 x 100
- Ask 2.0800 x 100
- Day's Range
1.9902 - 2.1200 - 52 Week Range
1.1100 - 3.2900 - Volume
176,095 - Avg. Volume
210,156 - Market Cap (intraday)
164.336M - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3700 - Earnings Date May 14, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.24
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
www.proqr.comRecent News: PRQR
Performance Overview: PRQR
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRQR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRQR
Valuation Measures
Market Cap
162.71M
Enterprise Value
57.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.31
Price/Book (mrq)
3.68
Enterprise Value/Revenue
8.75
Enterprise Value/EBITDA
-2.37
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.06%
Return on Equity (ttm)
-51.33%
Revenue (ttm)
6.59M
Net Income Avi to Common (ttm)
-28.12M
Diluted EPS (ttm)
-0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
118.92M
Total Debt/Equity (mrq)
47.68%
Levered Free Cash Flow (ttm)
62.8M